MIR330

Summary

MIR330 (microRNA 330, HGNC:31771) is a microRNA gene on chromosome 19q13.32.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 442902 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31771
Approved symbol	MIR330
Name	microRNA 330
Location	19q13.32
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-330
Ensembl gene	ENSG00000284544
Ensembl biotype	miRNA
Entrez	442902
RNAcentral	URS000075A0E5 — miRNA, 94 nt, 22 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362196

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362196 — 1 exons

Exon	Start	End
ENSE00001436959	45638994	45639087

Expression profiles

Bgee: expression breadth broad, 33 present calls, max score 72.94.

Top tissues by expression

33 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	72.94	gold quality
substantia nigra	UBERON:0002038	70.20	gold quality
left adrenal gland	UBERON:0001234	69.20	gold quality
Ammon’s horn	UBERON:0001954	67.58	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	67.42	gold quality
tibial artery	UBERON:0007610	66.74	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	66.09	gold quality
esophagus mucosa	UBERON:0002469	65.37	gold quality
heart left ventricle	UBERON:0002084	65.07	gold quality
skin of abdomen	UBERON:0001416	64.68	gold quality
ascending aorta	UBERON:0001496	64.25	gold quality
subcutaneous adipose tissue	UBERON:0002190	64.16	gold quality
putamen	UBERON:0001874	64.12	gold quality
small intestine Peyer’s patch	UBERON:0003454	63.59	gold quality
transverse colon	UBERON:0001157	63.47	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	63.05	gold quality
colon	UBERON:0001155	61.90	gold quality
muscle layer of sigmoid colon	UBERON:0035805	61.72	gold quality
skin of leg	UBERON:0001511	61.08	gold quality
right frontal lobe	UBERON:0002810	59.90	gold quality
vagina	UBERON:0000996	59.38	gold quality
tibial nerve	UBERON:0001323	58.40	gold quality
prostate gland	UBERON:0002367	57.17	gold quality
nucleus accumbens	UBERON:0001882	56.47	gold quality
right hemisphere of cerebellum	UBERON:0014890	56.11	gold quality
anterior cingulate cortex	UBERON:0009835	55.82	gold quality
caudate nucleus	UBERON:0001873	54.66	gold quality
hypothalamus	UBERON:0001898	54.30	gold quality
cerebellar hemisphere	UBERON:0002245	52.69	gold quality
left lobe of thyroid gland	UBERON:0001120	52.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• miR-330 induces apoptosis in prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. (PMID:19597470)
• these results establish a role of miR-330 in negatively regulating Cdc42 expression and colorectal cancer cell proliferation. (PMID:23337504)
• Overexpression of miR-330 by transfection of a chemically synthesized miR-330 mimic induced a reduction in expression levels of the Sp1 protein, accompanied by significant suppression of cellular migration and invasion capability. (PMID:23670210)
• This study provides further data for the identification of a miRNA profile for glioblastoma and suggests that different-grade neoplasia could be characterized by different expression of specific miRNAs. (PMID:24412053)
• MiR-330-3p and MAP2K5 are potentially important contributors to mood and anxiety-related traits (PMID:24436253)
• miR-330 negatively regulated the expression of SH3GL2 in GSCs, which promoted the oncogenic progression of GSCs through activating ERK and PI3K/AKT signaling pathways. (PMID:24736727)
• miR-330-5p is a potent negative regulator of TYR, but not of MITF, in pigmented melanoma cells and normal melanocytes (PMID:24862846)
• Knock-down of EGR2 with siRNA was demonstrated to have a similar effect as the over-expression of miR-330-3p in NSCLC cell lines (PMID:25935837)
• identified miR-29a and miR-330-5p as two new tumor suppressive miRNAs that inhibit the expression of MUC1 oncogenic mucin in pancreatic cancer cells. (PMID:26036346)
• In pre-treatment biopsies miR330 was the most downregulated miRNA in esophageal adenocarcinoma patients who subsequently failed to respond to neoCRT. The role of miR330 as modulator of response and sensitivity to CRT was further investigated in vitro. (PMID:26221725)
• miR-330-5p has a strong inhibitory effect on TIM-3 expression in acute myeloma leukaemia cell line (PMID:27341144)
• Findings suggested that miR-330-5p represents a potential tumor-suppressive miRNA and plays an important role in cutaneous malignant melanoma progression by suppressing TYR and PDIA3 expression. (PMID:27363653)
• These results suggest that downregulation of miR-330-5p expression may affect Colorectal cancerdevelopment via modulation of ITGA5 expression. (PMID:27633518)
• Upregulation of miR-330 is associated with poor prognosis and contributes to more aggressive phenotypes of Hepatocellular Carcinoma . The oncogenic role of miR-330 in Hepatocellular Carcinoma is linked to downregulation of ING4. (PMID:28050784)
• We show for the first time that miR-330-3p targets CCBE1 to promote invasion and metastasis. (PMID:28419078)
• miR-330 inhibits IL-22-induced proliferation of HaCaT and HKC cell by targeting CTNNB1. (PMID:28501007)
• our results indicate that miR-330-5p inhibits non-small-cell lung cancer (NSCLC) cell growth through downregulation of NOB1 expression. Our study suggests that miR-330-5p may serve as a potential therapeutic target for the treatment of NSCLC. (PMID:28849232)
• As a regulator of epithelial ovarian cancer (EOC) cell proliferation, metastasis, and chemoresistance, S100A7 represents a potential prognostic biomarker for EOC as well as a treatment target. Because miR-330-5p functions as an inhibitor of EOC cell growth and S100A7 expression, it promises to improve EOC outcomes. (PMID:29485916)
• MiR-330-3p acts as a tumor suppressor by regulating Bmi-1 expression in osteosarcoma. (PMID:29614499)
• DGCR5 can act as a crucial regulator of cancer stem cells in non small cell lung cancer by modulating miR-330-5p/CD44 axis. (PMID:29663359)
• miR-330-3p promoted metastasis of lung cancer cells by suppressing hSOD2b expression and unveiled a new clinical application of miR-330-3p in the therapy of lung cancer. (PMID:30192404)
• Inhibiting TPX2 by miR-330-3p suppresses the proliferation of melanoma cell lines; miR-330-3p/TPX2 pathway expressed differently between melanoma patients and healthy people (PMID:30257313)
• Low miR330 expression is associated with gastric cancer. (PMID:30281914)
• Circ_0078767 and RASSF1A were downregulated, while miR-330-3p was upregulated in non-small-cell lung cancer (NSCLC) than that in adjacent tissues. miR-330-3p had a binding relationship with circ_0078767 and RASSF1A. The overexpression of circ_0078767 and RASSF1A or the underexpression of miR-330-3p significantly suppressed NSCLC cell viability. (PMID:30507050)
• LINC00958 may bind to miR-330-5p to inhibit PAX8 in a competitive fashion, thereby preventing the progression of pancreatic cancer. (PMID:30639194)
• our data indicated that the LINC00052 also remarkably suppressed pancreatic tumor growth via modulating miR-330-3p in vivo (PMID:30712321)
• MiR-330 is highly expressed in cancer tissues and serum of patients with breast cancer, and it can promote the axillary lymph node metastasis, which is an important factor affecting the prognosis of breast cancer patients. However, no obvious correlations of the expression level of miR-330 with the tumor size, the histological grade, the HER2 expression and the expression of estrogen receptors are found. (PMID:30840281)
• lncRNA LINC00488 can competitively sponge miR-330-5p to regulate TLN1 in relation to the cell growth and angiogenesis in hepatocellular carcinoma. (PMID:31005556)
• Upregulated miR-330-5p may lead to unstable carotid plaques by targeting Talin-1 in symptomatic carotid stenosis patients. (PMID:31215474)
• MicroRNA-330 inhibits growth and migration of melanoma A375 cells: In vitro study. (PMID:31237010)
• Loss of miR-330-5p expression in OAC tumours may influence tumour cell invasive capacity, tumour growth and therapeutic sensitivity via alterations to the tumour microenvironment. (PMID:31391080)
• these results suggested that miR330 exhibits tumorsuppressor activity in the development of RB by directly targeting ROCK1, indicating that restoration of miR330 expression may be a promising therapeutic technique in the treatment of patients with retinoblastoma. (PMID:31432120)
• Abnormal expression and mechanism of miR-330-3p/BTG1 axis in hepatocellular carcinoma. (PMID:31486488)
• MicroRNA-330-3p promotes brain metastasis and epithelial-mesenchymal transition via GRIA3 in non-small cell lung cancer. (PMID:31498117)
• our study demonstrates that circPTN is upregulated in glioma tissues compared with normal brain tissue and contributes to the high proliferation activity of glioma cells by sponging miR-145-5p and miR-330-5p. Moreover, circPTN sponges miR-145-5p to promote the self-renewal of glioma stem cells, which is associated with tumorigenesis in glioma. (PMID:31511040)
• LncRNA TDRG1 functions as an oncogene in cervical cancer through sponging miR-330-5p to modulate ELK1 expression. (PMID:31539116)
• MicroRNA-330-5p promotes the development of osteosarcoma by regulating SPRY2. (PMID:31696462)
• HLA-F-AS1 also enhanced the expressions of PFN1, which was validated as a target gene of miR-330-3p. CONCLUSION: HLA-F-AS1 promoted colorectal cancer progression via regulating miR-330-3p/PFN1 axis (PMID:31863778)
• SNHG3 Functions as miRNA Sponge to Promote Breast Cancer Cells Growth Through the Metabolic Reprogramming. (PMID:31956955)
• Circulating miR-330-3p in Late Pregnancy is Associated with Pregnancy Outcomes Among Lean Women with GDM. (PMID:31969632)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir330	ENSMUSG00000065543
rattus_norvegicus	Mir330	ENSRNOG00000035565

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.